Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

67Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). © 2013 American Society for Blood and Marrow Transplantation.

Cite

CITATION STYLE

APA

Tanguy-Schmidt, A., Rousselot, P., Chalandon, Y., Cayuela, J. M., Hayette, S., Vekemans, M. C., … Thomas, X. (2013). Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. Biology of Blood and Marrow Transplantation, 19(1), 150–155. https://doi.org/10.1016/j.bbmt.2012.08.021

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free